ClinicalTrials.gg
RecruitingNCT07850934Updated Oct 22, 2026

Effect of Melatonin on Pulmonary Hypertension in Full Term Neonates

An interventional study of Melatonin and nitric oxide generator in Congenital Peumonia, Persistent Pulmonary Hypertension of Newborn and Congenital Diaphragmatic Hernia, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jul 2025, registered Aug 2026).
  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Oct 22, 2026Primary completion movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Sex
All
01

Study summary

The aim of the study

  1. To evaluate safety and efficacy of melatonin as an adjuvant therapy to inhaled nitric oxide generated by NO generator in the treatment of pulmonary hypertension in full term neonates.
  2. To assess the effect of inhaled nitric oxide and melatonin on cerebral perfusion.
Read the detailed description

Neonates fulfilling the inclusion criteria will be divided into 2 groups:

  1. Intervention group(26 Neonates) will receive iNO and melatonin

    1. iNO

      • iNO will be initiated at 20 ppm.
      • The expected clinical response will be improved oxygenation and cardio-respiratory stability in the first 30 minutes after initiation of iNO therapy.
      • If there is no clinical response, the iNO dose will be increased to up to 40 ppm.
      • If after 30 minutes there is no clinical response, iNO will be discontinued.
      • After clinical response iNO may be weaned by 50% every 4hours provided the oxygenation index remains at ≤10, pre-ductal SpO2 does not decrease by ≥5%, and/or FiO2 does not increase by ≥10%
      • When a dose of 5 ppm has been reached, iNO may be decreased by steps of 1 ppm (every 30 minutes to 2 h) until discontinuation, provided the infant remains well oxygenated at \<60% FiO2
      • Oxygen saturation index (OSI) replaces PaO2 with oxygen saturation as measured by pulse oximetry (SpO2) in the OI equation and is calculated as OSI = MAP × FIO2 × 100 / SpO2
    2. Melatonin will be given by nasogastric tube at a dose (3 mg/kg) divided every 8 hours till the end of iNO therapy
  2. Control group (26 Neonates) gestational age and weight matched to the intervention group and will receive only iNO with the same previous dose and manner.

In case of failure of either group, patient will receive rescue treatment as milrinone at a dose 0.375 µg/kg/min to a maximum 0.750 µg/kg/min intravenous infusion

Study Tools : All of the following data will be obtained:

  1. Full history taking: antenatal, natal and postnatal history.
  2. Gestational age and anthropometric measurements.
  3. Diagnosis of the patient and cause of pulmonary hypertension.
  4. Full clinical examination: including general, cardiopulmonary, abdominal, and neurological examination.
  5. Physiological parameters with special emphasis on heart rate, respiratory rate, oxygen saturation, blood pressure and fraction of inspired oxygen (FiO2) which will all be measured at baseline (just before iNO administration) and at pre-specified intervals (15, 30, 45, and 60 min) after iNO then every 3hours through the course of study.
  6. Management in NICU:

    1. Respiratory support type, mode of ventilation, duration, settings at the time of administration and throughout the course of study.
    2. Cardiac supports: type, dose and duration.
    3. Antibiotics: type and duration.
    4. Feeding: type (artificial or breast feeding), route and volume.
  7. Effectiveness of iNO will be assessed using oxygen saturation and fio2.
  8. ECHO: It will be done before starting therapy, after 24 hours and after completing the treatment

    1. Estimation of pulmonary artery pressure will be assessed by measuring tricuspid valve regurgitation peak velocity, pulmonary regurgitation peak velocity, transductal right-to-left flow peak velocity, and interventricular septum (IVS) configuration.
    2. Right ventricular function will be assessed by measuring tricuspid annular plane systolic excursion (TAPSE). Left ventricular function will be analyzed by ejection fraction (EF biplane Simpson).
    3. Assessment of the direction and peak flow velocity of transductal blood flow will indicate the relation between pulmonary and systemic pressures
  9. Transcranial ultrasound (TCUS): Will be done to measure the resistive index of middle cerebral artery before starting therapy and after 72hrs.
  10. Amplitude EEG: will be applied once diagnosed and throughout the course of the study. Double channel aEEG will be applied using 4 electrodes (C3 C4 P3 P4) electrodes and interpretation will be done by Burdjalov score
  11. Serum S100B will be measured 24 hours after diagnosis and starting the treatment with cut off value (≥ 0.10 µg/L) indicating neuronal damage
  12. Monitoring of complications:

    1. Monitoring signs of bleeding as epistaxis, hematemesis and bleeding from umbilical stump.
    2. Laboratory monitoring of bleeding by bleeding profile (PT, PTT, INR) and CBC according to NICU protocol.
    3. Methaemoglobin level: will be measured before starting treatment to exclude congenital methemoglobinemia which is >2% as seen in venous blood gases and throughout the study daily
    4. NO2 level will be measured continuously by NO generator device
02

Conditions studied

  • Congenital Peumonia
  • Persistent Pulmonary Hypertension of Newborn
  • Congenital Diaphragmatic Hernia

Keywords

  • Nitric oxide generator
  • Melatonin
03

In context

Persistent Fetal Circulation Syndrome

40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.

This study's planned enrollment of 52 is above the median of 42 across 22 interventional studies indexed under Persistent Fetal Circulation Syndrome.

Browse Persistent Fetal Circulation Syndrome studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Term neonates with gestational age ≥ 37 weeks.
  • Mean Pulmonary artery pressure greater than 25mmHg with clinical manifestations as tachypnea, tachycardia, hypoxemia and hypotension

Exclusion criteria

Exclusion criteria :

  • Congenital methemoglobinemia.
  • Major congenital cardiac anomalies especially duct dependent systemic circulation.
  • Bleeding tendency.
  • Patients on other pulmonary vasodilators
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    control

    Control group (26Neonates) gestational age and weight matched to the intervention group and will receive only iNO will be initiated at 20 ppm without melatonin The expected clinical response will be improved oxygenation and cardio-respiratory stability in the first 30 minutes after initiation of iNO therapy. If there is no clinical response, the iNO dose will be increased to up to 40 ppm. If after 30 minutes there is no clinical response, iNO will be discontinued

    Device: nitric oxide generator

  • Active comparator
    Melatonin

    Intervention group (26Neonates) will receive iNO and melatonin. melatonin will be given by nasogastric tube at a dose (3 mg/kg) divided every 8 hours till the end of iNO therapy

    Drug: Melatonin · Device: nitric oxide generator

Interventions

  • Melatonin will be given by nasogastric tube at a dose (3 mg/kg) divided every 8 hours till the end of iNO therapy

  • Devicenitric oxide generator

    iNO will be initiated at 20 ppm. The expected clinical response will be improved oxygenation and cardio-respiratory stability in the first 30 minutes after initiation of iNO therapy.If there is no clinical response, the iNO dose will be increased to up to 40 ppm. If after 30 minutes there is no clinical response, iNO will be discontinued

06

What researchers measure

Primary outcomes

  1. melatonin as an adjuvant therapy to iNO

    1. oxygen saturation % every 3hrs 2. Fraction of inspired oxygen (FiO2) % which will all be measured at baseline (just before iNO administration) and at pre-specified intervals (15, 30, 45, and 60 min) after iNO then every 3hours through the course of study.

    Time frame: 72 hours

Secondary outcomes

  1. effect of iNO and melatonin on cerebral perfusion.

    Serum S100B will be measured 24 hours after diagnosis cut off value (≥ 0.10 µg/L) .

    Time frame: 24 hours

Other outcomes

  1. Effect of iNO and Melatonin on cerebral perfusion

    middle cerebral artery resistive index will be measured before and after starting therapy cutoff value 0.67-0.68

    Time frame: 72 hours

  2. Effect of iNO and Melatonin on electroencephalogram

    Burdjalov score before starting treatment during study after completion of therapy. a total ranging from 0 to 13, with higher values indicating a more mature and better organized background.

    Time frame: 72 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2026
First posted
Sep 30, 2026
StartActual
Jul 1, 2025
Primary completionEst.
Nov 1, 2026was Oct 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Nov 1, 2026
Oct 22, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Oct 22, 2026
    Primary completion Oct 1, 2026→Nov 1, 2026
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07850934
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Jul 1, 2025
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 22, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion